Competition adsorption of malachite green and rhodamine B on polyethylene and polyvinyl chloride microplastics in aqueous environment

Microplastics (MPs) will cause compound pollution by combining with organic pollutants in the aqueous environment. It is important for environmental protection to study the adsorption mechanism of different MPs for pollutants. In this study, the adsorption behaviors of malachite green (MG) and rhodamine B (RhB) on polyethylene (PE) and polyvinyl chloride (PVC) were studied in single systems and binary systems, separately. The results show that in single system, the adsorptions of between MPs for pollutants (MG and RhB) are more consistent with the pseudo-second-order kinetics and Freundlich isotherm model, the adsorption capacity of both MPs for MG is greater than that of RhB. The adsorption capacities of MG and RhB were 7.68 mg/g and 2.83 mg/g for PVC, 4.52 mg/g and 1.27 mg/g for PE. In the binary system, there exist competitive adsorption between MG and RhB on MPs. And the adsorption capacities of PVC for the two dyes are stronger than those of PE. This is attributed to the strong halogen-hydrogen bond between the two dyes and PVC, and the larger specific surface area of PVC. This study revealed the interaction and competitive adsorption mechanism between binary dyes and MPs, which is of great significance for understanding the interactions between dyes and MPs in the multi-component systems.publishedVersio

Evaluation of Essential and Toxic Elements in Blood Samples of Male Smokers Having Different Types of Cancers with Reference to Healthy Male Smokers

Immense epidemiologic studies have been reported about the role of essential trace and toxic elements as risk factors for incidence of different type of cancers in population of developed and developing countries. In present work the levels of carcinogenic, Arsenic, Cadmium, and Nickel (As, Cd and Ni) and anti-carcinogenic, Zinc and Selenium (Zn and Se) elements were measured in blood of male cancer patients (urinary bladder, lung, mouth and esophageal) and healthy referents. The all patients and referents were smoker. The blood samples were analysed with atomic absorption spectrometry after microwave assisted acid digestion. The resulted data indicated that the levels of toxic elements As, Ni and Cd were considerably elevated whereas essential elements, Zn and Se were lower in blood samples of all cancer cases as compared to those values found in noncancerous subjects. As the levels of essential trace elements were low in blood samples of male cancerous patients but difference was highly significant in lung and mouth cancer subjects (p<0.001), whereas sequence of decreasing order was not uniform. The levels of Zn in blood samples of different cancerous patients were found in decreasing order as: esophagus< mouth< urinary bladder<lung, whereas in case of Se as mouth<lung<urinary bladder<esophagus.The study revealed that the carcinogenic processes are significantly affecting the essential and toxic elements levels in biological samples of cancerous patients as related to those obtained for controls/referents

Artificial Intelligence Modeling-Based Optimization of an Industrial-Scale Steam Turbine for Moving toward Net-Zero in the Energy Sector

Augmentation of energy efficiency in the power generation systems can aid in decarbonizing the energy sector, which is also recognized by the International Energy Agency (IEA) as a solution to attain net-zero from the energy sector. With this reference, this article presents a framework incorporating artificial intelligence (AI) for improving the isentropic efficiency of a high-pressure (HP) steam turbine installed at a supercritical power plant. The data of the operating parameters taken from a supercritical 660 MW coal-fired power plant is well-distributed in the input and output spaces of the operating parameters. Based on hyperparameter tuning, two advanced AI modeling algorithms, i.e., artificial neural network (ANN) and support vector machine (SVM), are trained and, subsequently, validated. ANN, as turned out to be a better-performing model, is utilized to conduct the Monte Carlo technique-based sensitivity analysis toward the high-pressure (HP) turbine efficiency. Subsequently, the ANN model is deployed for evaluating the impact of individual or combination of operating parameters on the HP turbine efficiency under three real-power generation capacities of the power plant. The parametric study and nonlinear programming-based optimization techniques are applied to optimize the HP turbine efficiency. It is estimated that the HP turbine efficiency can be improved by 1.43, 5.09, and 3.40% as compared to that of the average values of input parameters for half-load, mid-load, and full-load power generation modes, respectively. The annual reduction in CO2 measuring 58.3, 123.5, and 70.8 kilo ton/year (kt/y) corresponds to half-load, mid-load, and full load, respectively, and noticeable mitigation of SO2, CH4, N2O, and Hg emissions is estimated for the three power generation modes of the power plant. The AI-based modeling and optimization analysis is conducted to enhance the operation excellence of the industrial-scale steam turbine that promotes higher-energy efficiency and contributes to the net-zero target from the energy sector

Performance evaluation of phosphonium based deep eutectic solvents coated cerium oxide nanoparticles for CO2 capture

The critical challenge being faced by our current modern society on a global scale is to reduce the surging effects of climate change and global warming, being caused by anthropogenic emissions of CO2 in the environment. Present study reports the surface driven adsorption potential of deep eutectic solvents (DESs) surface functionalized cerium oxide nanoparticles (CeNPs) for low pressure CO2 separation. The phosphonium based DESs were prepared using tetra butyl phosphoniumbromide as hydrogen bond acceptor (HBA) and 6 acids as hydrogen bond donors (HBDs). The as-developed DESs were characterized and employed for the surface functionalization of CeNPs with their subsequent utilization in adsorption-based CO2 adsorption. The synthesis of as-prepared DESs was confirmed through FTIR measurements and absence of precipitates, revealed through visual observations. It was found that DES6 surface functionalized CeNPs demonstrated 27% higher adsorption performance for CO2 capturing. On the contrary, DES3 coated CeNPs exhibited the least adsorption progress for CO2 separation. The higher adsorption performance associated with DES6 coated CeNPs was due to enhanced surface affinity with CO2 molecules that must have facilitated the mass transport characteristics and resulted an enhancement in CO2 adsorption performance. Carboxylic groups could have generated an electric field inside the pores to attract more polarizable adsorbates including CO2, are responsible for the relatively high values of CO2 adsorption. The quadruple movement of the CO2 molecules with the electron-deficient and pluralizable nature led to the enhancement of the interactive forces between the CO2 molecules and the CeNPs decorated with the carboxylic group hydrogen bond donor rich DES. The current findings may disclose the new research horizons and theoretical guidance for reduction in the environmental effects associated with uncontrolled CO2 emission via employing DES surface coated potential CeNPs

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

Background: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. Methods: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). Findings: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29–146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0– 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25–1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39–1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65–1·60]; p=0·92). Interpretation: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial

BACKGROUND: Antiplatelet therapy reduces the risk of major vascular events for people with occlusive vascular disease, although it might increase the risk of intracranial haemorrhage. Patients surviving the commonest subtype of intracranial haemorrhage, intracerebral haemorrhage, are at risk of both haemorrhagic and occlusive vascular events, but whether antiplatelet therapy can be used safely is unclear. We aimed to estimate the relative and absolute effects of antiplatelet therapy on recurrent intracerebral haemorrhage and whether this risk might exceed any reduction of occlusive vascular events. METHODS: The REstart or STop Antithrombotics Randomised Trial (RESTART) was a prospective, randomised, open-label, blinded endpoint, parallel-group trial at 122 hospitals in the UK. We recruited adults (≥18 years) who were taking antithrombotic (antiplatelet or anticoagulant) therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage, discontinued antithrombotic therapy, and survived for 24 h. Computerised randomisation incorporating minimisation allocated participants (1:1) to start or avoid antiplatelet therapy. We followed participants for the primary outcome (recurrent symptomatic intracerebral haemorrhage) for up to 5 years. We analysed data from all randomised participants using Cox proportional hazards regression, adjusted for minimisation covariates. This trial is registered with ISRCTN (number ISRCTN71907627). FINDINGS: Between May 22, 2013, and May 31, 2018, 537 participants were recruited a median of 76 days (IQR 29-146) after intracerebral haemorrhage onset: 268 were assigned to start and 269 (one withdrew) to avoid antiplatelet therapy. Participants were followed for a median of 2·0 years (IQR [1·0- 3·0]; completeness 99·3%). 12 (4%) of 268 participants allocated to antiplatelet therapy had recurrence of intracerebral haemorrhage compared with 23 (9%) of 268 participants allocated to avoid antiplatelet therapy (adjusted hazard ratio 0·51 [95% CI 0·25-1·03]; p=0·060). 18 (7%) participants allocated to antiplatelet therapy experienced major haemorrhagic events compared with 25 (9%) participants allocated to avoid antiplatelet therapy (0·71 [0·39-1·30]; p=0·27), and 39 [15%] participants allocated to antiplatelet therapy had major occlusive vascular events compared with 38 [14%] allocated to avoid antiplatelet therapy (1·02 [0·65-1·60]; p=0·92). INTERPRETATION: These results exclude all but a very modest increase in the risk of recurrent intracerebral haemorrhage with antiplatelet therapy for patients on antithrombotic therapy for the prevention of occlusive vascular disease when they developed intracerebral haemorrhage. The risk of recurrent intracerebral haemorrhage is probably too small to exceed the established benefits of antiplatelet therapy for secondary prevention. FUNDING: British Heart Foundation

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma

Background: Outcome in multiple myeloma (MM) has improved substantially over recent years as a result of the availability of multiple novel agents with acceptable safety profile. Study Design: Prospective observational study at a tertiary care institute. Methods: Twenty-five newly diagnosed patients of MM were treated with bortezomib and dexamethasone induction with monitoring for response and safety, followed by peripheral blood autologous stem cell transplant (PBASCT) in eligible patients or maintenance. Results: Out of 25 patients, 32% attained complete response (CR), 56% very good partial response (VGPR), 4% PR, and 8% showed no response. The overall response rate was 92%. In our study, 56% of patients showed hematological side effects, out of which thrombocytopenia was seen in 32%, anemia in 16%, and leukopenia in 8%. Six patients developed bortezomib-induced peripheral neuropathy, out of which four had grade 1 (66.66%), one had grade 2 (16.66%), and 1 (16.66%) had grade 3 toxicity. Sixteen patients were eligible for PBASCT, out of which eight patients received this therapy while as remaining eight patients opted for two more cycles of induction therapy followed by maintenance. After completing 18 months of maintenance, all the eight patients who underwent PBASCT were in CR. Out of the 15 patients who did not receive PBASCT five attained CR, eight VGPR while as two patients relapsed. Conclusion: Bortezomib plus dexamethasone is highly effective and well-tolerated regimen for frontline treatment of MM with a higher quality of response in an advanced stage and renal failure patients

Hysteresis Analysis of Hole-Transport-Material-Free Monolithic Perovskite Solar Cells with Carbon Counter Electrode by Current Density–Voltage and Impedance Spectra Measurements

Due to the tremendous increase in power conversion efficiency (PCE) of organic–inorganic perovskite solar cells (PSCs), this technology has attracted much attention. Despite being the fastest-growing photovoltaic technology to date, bottlenecks such as current density–voltage (J–V) hysteresis have significantly limited further development. Current density measurements performed with different sweep scan speeds exhibit hysteresis and the photovoltaic parameters extracted from the current density–voltage measurements for both scan directions become questionable. A current density–voltage measurement protocol needs to be established which can be used to achieve reproducible results and to compare devices made in different laboratories. In this work, we report a hysteresis analysis of a hole-transport-material-free (HTM-free) carbon-counter-electrode-based PSC conducted by current density–voltage and impedance spectra measurements. The effect of sweep scan direction and time delay was examined on the J–V characteristics of the device. The hysteresis was observed to be strongly sweep scan direction and time delay dependent and decreased as the delay increased. The J–V analysis conducted in the reverse sweep scan direction at a lower sweep time delay of 0.2 s revealed very large increases in the short circuit current density and the power conversion efficiency of 57.7% and 56.1%, respectively, compared with the values obtained during the forward scan under the same conditions. Impedance spectroscopy (IS) investigations were carried out and the effects of sweep scan speed, time delay, and frequency were analyzed. The hysteresis was observed to be strongly sweep scan direction, sweep time delay, and frequency dependent. The correlation between J–V and IS data is provided. The wealth of photovoltaic and impendence spectroscopic data reported in this work on the hysteresis study of the HTM-free PSC may help in establishing a current density–voltage measurement protocol, identifying components and interfaces causing the hysteresis, and modeling of PSCs, eventually benefiting device performance and long-term stability